ArticleInnovation (Cambridge (Mass.))2024
An engineered Cas12i nuclease that is an efficient genome editing tool in animals and plants.
Article in Innovation (Cambridge (Mass.)), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 37 citations in OpenAlex.
- Optimizations of Cas12a- and Cas12i-based adenine base editors for efficient precision editing in the plant genome.Journal of integrative plant biology · 2026Article
- Strategies and mechanisms of precision genome engineering: From gene editing to genome writing.iMetaOmics · 2026Review
- Coupling of both a transactivation module and a double-stranded DNA-binding domain boosts Cas12i3 variant-based cytosine and adenine editing in plants.Journal of integrative plant biology · 2026Article
- Efficient CRISPR/Cas-SF01 genome editing tools with high editing efficiency in allotetraploid oilseed rape.Journal of integrative plant biology · 2026Article
- Enhanced Cas12i3 system enables precise OsAUX3 editing for rice grain improvement.Journal of integrative plant biology · 2026Article
- Optimized Cas-SF01 gene-editing toolbox shortens flowering timing in commercial maize inbred JING724.Journal of integrative plant biology · 2026Article
- Base editing in rice using nuclease-deactivated CRISPR/Cas-SF01.Journal of integrative plant biology · 2026Article
- Developing a robust multiplex CRISPR/Cas12i3-5M system for trait stacking in soybean.Journal of integrative plant biology · 2026Article
- Synergistic engineering of Casδ nuclease for robust genome editing.Journal of integrative plant biology · 2026Article
- CasY7: An optimized Cas12i system for enhanced genome editing in monocot crops.Journal of integrative plant biology · 2026Article
- Crops exposed to extreme conditions: perspectives of gene editing to improve stress tolerance.Plant cell reports · 2026Review
- Improving growth performance across multiple sheep breeds by targeting the MSTN gene using an enhanced Cas12i system.Science China. Life sciences · 2026Article
- mRNA-engineered CRISPR-Cas epigenetic editors enable durable and efficient gene silencingInnovation (Cambridge (Mass.)) · 2026Article
- Structure-Guided Engineering of a Cas12i Nuclease Unlocks Near-PAMless Genome Editing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Improved efficiency of genetic transformation for the development of elite germplasm using CRISPR/Cas12i3 in maize.aBIOTECH · 2026Article
- PRICE: direct and robust detection of microRNAs at single-nucleotide resolution.Nature communications · 2026Article
- Casδ, an evolutionary transitional CRISPR system enables efficient genome editing across animals and plants.Nucleic acids research · 2025Article
- Effects ofAnimals : an open access journal from MDPI · 2025Article
- Engineered Cas12j-8 is a Versatile Platform for Multiplexed Genome Modulation in Mammalian Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- An engineered CRISPR-Cas12i tool for efficient multiplexed genome editing.Nucleic acids research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The type V-I CRISPR-Cas system is becoming increasingly more attractive for genome editing. However, natural nucleases of this system often exhibit low efficiency, limiting their application. Here, we used structure-guided rational design and protein engineering to optimize an uncharacterized Cas12i nuclease, Cas12i3. As a result, we developed Cas-SF01, a Cas12i3 variant that exhibits significantly improved gene editing activity in mammalian cells. Cas-SF01 shows comparable or superior editing performance compared to SpCas9 and other Cas12 nucleases. Compared to natural Cas12i3, Cas-SF01 has an expanded PAM range and effectively recognizes NTTN and noncanonical NATN and TTVN PAMs. In addition, we identified an amino acid substitution, D876R, that markedly reduced the off-target effect while maintaining high on-target activity, leading to the development of Cas-SF01
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.